Compare MXL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | IBRX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.5B |
| IPO Year | 2009 | 2015 |
| Metric | MXL | IBRX |
|---|---|---|
| Price | $70.20 | $7.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $41.67 | $12.57 |
| AVG Volume (30 Days) | 3.8M | ★ 9.5M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.08 | 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $478,596,000.00 | $113,288,000.00 |
| Revenue This Year | $22.10 | $88.59 |
| Revenue Next Year | $10.70 | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $12.77 | $1.95 |
| 52 Week High | $128.30 | $12.43 |
| Indicator | MXL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 45.44 |
| Support Level | $15.70 | $6.68 |
| Resistance Level | $100.90 | $8.46 |
| Average True Range (ATR) | 7.32 | 0.41 |
| MACD | -0.60 | -0.02 |
| Stochastic Oscillator | 22.17 | 38.26 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.